SecBot SecBot
PRESS-RELEASE ·Filed Mar 12, 2026

ORKA

Oruka Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Investors should monitor the upcoming 16-week data readout for ORKA-001 in 2Q 2026 as a key catalyst; the accelerated timeline may signal strong trial performance and could positively impact sentiment if results are robust.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$40.00
T+0 close · Mar 12, 2026 · via day close
Latest settled
+60.15%
T+60 · $64.06
Vs SPY
+48.54%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 13 $40.00entry
  2. T+1 · 8mo ago +4.38%α +3.35% · $41.75
  3. T+5 · 8mo ago −2.73%α −0.61% · $38.91
  4. T+20 · 7mo ago +53.45%α +49.86% · $61.38
  5. T+60 · 5mo ago +60.15%α +48.54% · $64.06
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oruka Therapeutics reported fourth quarter and full year 2025 financial results, highlighted by $479.6 million in cash and advancement of its two lead programs: ORKA-001 and ORKA-002. Enrollment in the EVERLAST-A trial for ORKA-001 completed ahead of schedule, with 16-week data now expected in 2Q 2026. The Phase 2 ORCA-SURGE trial for ORKA-002 in psoriasis has been initiated, with data anticipated in 2027.

Key Financial Metrics

EPS
$-1.85

Key Facts

  • Cash, cash equivalents, and marketable securities totaled $479.6 million as of December 31, 2025.
  • Net loss was $29.6 million in Q4 2025 and $105.4 million for the full year 2025.
  • R&D expenses were $27.6 million in Q4 2025 and $100.6 million for the full year 2025.
  • Enrollment in EVERLAST-A (ORKA-001) completed in December 2025; 16-week data expected in 2Q 2026.
  • ORCA-SURGE Phase 2 trial for ORKA-002 in psoriasis initiated in February 2026, with data expected in 2027.

Financial Impact

Increased R&D and G&A spending led to higher net loss in 2025 vs. prior period, but strong cash position supports continued development.

net lossr&d expensescash position

Risk Factors

  • Clinical development risk: Data from ORKA-001 and ORKA-002 may not meet efficacy or safety expectations.
  • Dilution risk: Future capital raises may be necessary beyond 2027, depending on burn rate and development costs.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3255109

Track record

40 reports on ORKA

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 11 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
  3. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
  4. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
  5. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  6. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  7. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
  8. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  9. Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  10. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
Showing 10 of 40

US Market Status

Market Closed · Opens Wed (9h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 12, 2026